Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Jayanthi Lea"'
Autor:
Elizabeth Kvale, Farya Phillips, Samiran Ghosh, Jayanthi Lea, Claire Hoppenot, Anthony Costales, Jan Sunde, Hoda Badr, Eberechi Nwogu-Onyemkpa, Nimrah Saleem, Rikki Ward, Bijal Balasubramanian
Publikováno v:
JMIR Research Protocols, Vol 13, p e48069 (2024)
BackgroundOvarian cancer ranks 12th in cancer incidence among women in the United States and 5th among causes of cancer-related death. The typical treatment of ovarian cancer focuses on disease management, with little attention given to the survivors
Externí odkaz:
https://doaj.org/article/e385fdae722c436aa802fa17a630b373
Publikováno v:
Gynecologic Oncology Reports, Vol 48, Iss , Pp S1-S2 (2023)
Objectives: Immunotherapy (IO), either as single agent or in combination (ex: pembrolizumab +/– lenvatinib), is a critical tool in the treatment of advanced/metastatic endometrial cancer (EC). In other tumor types, the incidence of immune related a
Externí odkaz:
https://doaj.org/article/bedc826bd81a4f56b739227d5365dec9
Publikováno v:
Gynecologic Oncology Reports, Vol 48, Iss , Pp S13- (2023)
Objectives: PARP proteins are regulators of DNA damage repair in the cell. PARP inhibitors (PARPi) are a class of drugs used to treat ovarian cancer especially in patients with BRCA 1/2 gene mutations and homologous recombination deficiencies. These
Externí odkaz:
https://doaj.org/article/af268d809c5041b996de63df4a0036a0
Autor:
Steven Blaine Holloway, Vinita Popat, NeChelle Keaton, Melanie R. King, Awanna Hawthorne, Jayanthi Lea
Publikováno v:
Gynecologic Oncology Reports, Vol 48, Iss , Pp S23-S24 (2023)
Objectives: Combination pembrolizumab with lenvatinib (len/pem) has revolutionized second-line treatment and survival outcomes for patients with mismatch repair-proficient (MMRp) recurrent endometrial cancer (EC). We sought to define existing barrier
Externí odkaz:
https://doaj.org/article/216a1074abdb4ad98631de6b3611cd09
Autor:
Lydia M. Makepeace, Alexandra N. Spirtos, Anjali Nambiar, Aldeboran N. Rodriguez, Elaine Duryea, Catherine Y. Spong, Jayanthi Lea
Publikováno v:
Gynecologic Oncology Reports, Vol 48, Iss , Pp S30-S31 (2023)
Objectives: Cervical cancer (CC) occurs in 0.1–12 per 10,000 pregnancies. Management of these patients is largely based on case reports and expert opinion. While data suggests that pregnancy does not adversely affect oncologic outcomes, timing and
Externí odkaz:
https://doaj.org/article/2f88c25c1dd64ae893023f36542597c1
Autor:
Xuexin Yu, Wanrun Lin, Alexandra Spirtos, Yan Wang, Hao Chen, Jianfeng Ye, Jessica Parker, Ci Ci Liu, Yiying Wang, Gabriella Quinn, Feng Zhou, Setsuko K. Chambers, Cheryl Lewis, Jayanthi Lea, Bo Li, Wenxin Zheng
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-14 (2022)
Abstract Background High-grade serous carcinoma (HGSC) is the most frequent and lethal type of ovarian cancer. It has been proposed that tubal secretory cells are the origin of ovarian HGSC in women with familial BRCA1/2 mutations. However, the molec
Externí odkaz:
https://doaj.org/article/a8e79e8e9c274f5f8fc2ac3504508819
Autor:
Jian Wang, Min Luo, Xinyu Zhang, Jinming Gao, Gang Huang, Jayanthi Lea, Yuwei Li, Jun Cao, Xiaoyi Jiang, Xichen Zheng, Zhida Liu, Jonathan Wilhelm, Jinlan Zhang, Baran Sumer, Zhigang Lu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 5 (2022)
Background Cancer vaccines are able to achieve tumor-specific immune editing in early-phase clinical trials. However, the infiltration of cytotoxic T cells into immune-deserted tumors is still a major limiting factor. An optimized vaccine approach to
Externí odkaz:
https://doaj.org/article/49477d19cd224b38804ffb63795be6eb
Autor:
Jared Ostmeyer, Elena Lucas, Scott Christley, Jayanthi Lea, Nancy Monson, Jasmin Tiro, Lindsay G Cowell
Publikováno v:
PLoS ONE, Vol 15, Iss 3, p e0229569 (2020)
We previously showed, in a pilot study with publicly available data, that T cell receptor (TCR) repertoires from tumor infiltrating lymphocytes (TILs) could be distinguished from adjacent healthy tissue repertoires by the presence of TCRs bearing spe
Externí odkaz:
https://doaj.org/article/43eeec495e79432c8f0661f08187e763
Autor:
Sarah Bedell, Dustin Manders, David Miller, Jayanthi Lea, Siobhan Kehoe, Debra Richardson, Matthew Carlson
Publikováno v:
Gynecologic Oncology Reports, Vol 20, Iss C, p 139 (2017)
Externí odkaz:
https://doaj.org/article/05f7465833464f138f855632134c9757
Autor:
Nadeem Abu-Rustum, Catheryn Yashar, Rebecca Arend, Emma Barber, Kristin Bradley, Rebecca Brooks, Susana M. Campos, Junzo Chino, Hye Sook Chon, Christina Chu, Marta Ann Crispens, Shari Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Robert Giuntoli, Ernest Han, Jordan Holmes, Brooke E. Howitt, Jayanthi Lea, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Mirna Podoll, Ritu Salani, John Schorge, Jean Siedel, Rachel Sisodia, Pamela Soliman, Stefanie Ueda, Renata Urban, Stephanie L. Wethington, Emily Wyse, Kristine Zanotti, Nicole R. McMillian, Shaili Aggarwal
Publikováno v:
Journal of the National Comprehensive Cancer Network. 21:181-209
Adenocarcinoma of the endometrium (also known as endometrial cancer, or more broadly as uterine cancer or carcinoma of the uterine corpus) is the most common malignancy of the female genital tract in the United States. It is estimated that 65,950 new